GBS News and Press, GBS Inc. From 02/10/22

GBS Inc. (GBS) Q2 2022 Results Conference Call February 10, 2021 04:30 PM ET Company Participants Tim McCarthy - Investor Relations Steven Boyages - Chairman and Chief Executive Officer Spiro Sakiris - Chief Financial Officer Conference Call Participants John Vandermosten - Zacks Small Capita...

- Discussions underway between the University of Newcastle and GBS to oversee the high-tech manufacturing facility supported by its $4.7 Million Grant Funding Award from Australian Government - - $11.19 Million in Cash, Cash Equivalents, and Marketable Securities as of Dec...

NEW YORK, Feb. 07, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced that it will release its financial results for the seco...

Can-Fite BioPharma (NYSE:CANF) +71% liver cancer patient treated with can-Fite’s Namodenoson clears all cancer lesions under open label extension of phase II study. Society Pass Incorporated (NASDAQ:SOPA) +35% on being added to the Russell 2000 Index. Verso (NYSE:VRS) +3...

NEW YORK, Dec. 20, 2021 (GLOBE NEWSWIRE) -- GBS (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced that Dr. Steven Boyages, GBS’ interim CEO and Chairm...

NEW YORK, Dec. 13, 2021 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced that in collaboration with Life Science Biosensor Diagn...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Today, shares of GBS (NASDAQ: GBS ) are skyrocketing following news that “the company will start preparation for clinical trials of its rapid SARS-CoV-2 antibody test.” GBS’s antibody test utili...

Gainers: Cumberland Pharmaceuticals (NASDAQ:CPIX) +134%. GBS (NASDAQ:GBS) +43%. ImmunoGen (NASDAQ:IMGN) +31%. RenovoRx (NASDAQ:RNXT) +30%. Adagio (NASDAQ:ADGI) +25%. Losers: Triumph Group (NYSE:TGI) -14%. Recruiter (NASDAQ:RCRT) -12%. Hexcel (NYSE:HXL) -10%. United Airlines (NASDAQ:UAL) -10%....

GBS (NASDAQ:GBS) gains 7.4% premarket after announcing that it will commence preparation for clinical trials of its rapid SARS-CoV-2 Antibody test following the recent successful completion of a clinical validation study. The objective of this study was to develop a diagnostic ...

Cumberland Pharmaceuticals CPIX +90% on FDA label expansion for pain therapy Pioneer Power Solutions (NASDAQ:PPSI) +66%. First Wave BioPharma (NASDAQ:FWBI) +53% announces independent data monitoring committee provides positive interim safety assessment for part 2 COVID-19 RESER...